Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Certified by Founder
Lodge
Evommune
start up
United States
- Palo Alto, California
- 27/04/2023
- Series B
- $50,000,000
Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.
Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease.
Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.
- Industry Biotechnology Research
- Website https://www.evommune.com/
- LinkedIn https://www.linkedin.com/company/evommune/
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)